On Oct 25, 2018 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), reported a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, reported that investigators at Emory University will present animal model data supporting the potential of WP1066 to treat pediatric brain tumors at the upcoming Society for Neuro-Oncology Annual Scientific Meeting (Press release, Moleculin, OCT 25, 2018, View Source [SID1234530259]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"A number of independent institutions have published results supporting the potential for WP1066 to kill tumors in a range of animal models," commented Walter Klemp, Moleculin’s Chairman and CEO. "Having this corroborated yet again by data presented from Emory University just adds to the enthusiasm for testing WP1066 in humans. What makes this particularly important is that our drug showed activity against the most common form of childhood brain tumor, medulloblastoma, for which there is a desperate need for more effective treatments."

Mr. Klemp continued, "We are also proud of the fact that two different Moleculin technologies, WP1066 and WP1122 (see Moleculin press release dated October 10, 2018), are being presented at this prestigious conference on brain tumors. We believe this is a strong indicator of the breadth and significance of our development pipeline

On October 24, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported that the Company expects to report financial results for the third quarter of 2018 after 5:00 p.m. ET on Tuesday, November 6, 2018 (Press release, Supernus, OCT 24, 2018, View Source [SID1234530634]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to present the third quarter 2018 business results on Wednesday, November 7, 2018 at 9:00 a.m. ET. Following management’s prepared analysis and discussion of business results, the call will be open for questions.

A live webcast will be available at www.supernus.com.

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference dial-in:

(877) 288-1043

International dial-in:

(970) 315-0267

Conference ID:

2697616

Conference Call Name:

Supernus Pharmaceuticals Third Quarter 2018 Earnings

Conference Call

Following the live call, a replay will be available on the Company’s website under the ‘Investors’ section. The webcast will be available on the Company’s website for 60 days following the live call.

On October, 26 2018 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) reported that it will host a conference call and live webcast to report its 2018 third quarter financial results on Thursday, November 8, 2018 at 4:30 p.m. ET (Press release, Inovio, OCT 24, 2018, View Source [SID1234530154]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live and archived version of the audio presentation will be available online at View Source This is a listen-only event but will include a live Q&A with analysts.

A replay of the conference call will be accessible two hours after the call at 877-481-4010 (domestic) or 919-882-2331 (international) using replay ID 39603.

On October 24, 2018 Agilent Technologies Inc. (NYSE: A) reported that it will release fourth-quarter fiscal 2018 financial results after the stock market closes on November 19 (Press release, Agilent, OCT 24, 2018, http://www.agilent.com/about/newsroom/presrel/2018/24oct-gp18056.html [SID1234530244]). The company will host a live webcast of its investor conference call in listen-only mode.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Monday, November 19, 2018
Time: 1:30 PM (Pacific Time)
Web access: http://www.investor.agilent.com

Listeners may log on and select "Q4 2018 Agilent Technologies Inc. Earnings Conference Call" in the "News & Events — Calendar of Events" section. The webcast will remain on the company site for 90 days.

In addition, a telephone replay of the conference call will be available at approximately November 19, 2018 at 4: 30 PM (Pacific Time) after the call and through November 26 by dialing +1 855-859-2056 (or +1 404-537-3406 from outside the United States) and entering pass code 6519506.

On October 24, 2018 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) reported that members of the Company’s executive team will attend the BIO-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark on November 5-7, 2018 (Press release, Actinium Pharmaceuticals, OCT 24, 2018, View Source [SID1234530261]). BIO-Europe is the largest life science partnering event in Europe that is expected to draw over 4,000 attendees from over 2,000 companies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Actinium is developing Antibody Radio-Conjugates (ARCs) that deliver radioisotopes in a targeted manner to cells expressing CD45 and CD33 for multiple hematologic indications. Actinium is the only company with multi-disease, multi-target pipeline focused on improving access and outcomes to cellular therapies including bone marrow transplant and CAR-T through targeted conditioning. Actinium’s lead targeted conditioning product candidate, Iomab-B, is currently being studied in a pivotal Phase 3 trial. Actinium’s best-in-class CD33 program is being studied in multiple trials as both a targeted conditioning agent and therapeutic for patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome and Multiple Myeloma. Underpinning Actinium’s clinical programs is its Antibody Warhead Enabling technology that has been studied in both hematologic and solid tumors, which could be utilized to create ARCs for numerous targets and indications.

Sandesh Seth, Actinium’s Chairman and Chief Executive Officer said, "We are particularly excited for this year’s BIO-Europe Partnering Conference for a multitude of reasons. Given the progress and expansion of our targeted conditioning pipeline combined with the strong interest for radiopharmaceutical therapies of late, we look forward to what we expect to be a productive and valuable conference. First and foremost, we will be able to highlight extensive clinical data from our highly differentiated CD45 and CD33 ARCs for targeted conditioning and therapeutic indications, which have been studied in over 600 patients across 14 clinical trials. We will also showcase our recently unveiled Iomab-ACT program that we intend to make a universally available next generation lymphodepletion solution prior to CAR-T therapy. Additionally, we will present our AWE technology platform to potential collaborators and partners just as we have with our established AWE collaborator Astellas Pharma, Inc."

Conference attendees may schedule a meeting with Actinium’s management through the conference’s partnering system View Source or by contacting Steve O’Loughlin, Actinium’s Principal Financial Officer, [email protected].

About BIO-Europe

The 24th annual BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify, engage and enter strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful business partnerships. BIO-Europe is organized by EBD Group, the leading partnering firm for the global biotechnology industry, in alliance with the Biotechnology Industry Organization (BIO)